Zobrazeno 1 - 10
of 120
pro vyhledávání: '"Patricia A Bradford"'
Publikováno v:
Journal of Antimicrobial Chemotherapy. 78:871-892
As one of a series of thematically linked reviews of the primary pharmacology of the β-lactam/β-lactamase inhibitor combination, ceftazidime/avibactam, this article reviews the microbiological findings in drug-exposed patients. Earlier articles in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::731987dc006077bd7f5da7783ddf6edf
https://doi.org/10.1093/jac/dkad049
https://doi.org/10.1093/jac/dkad049
Publikováno v:
Journal of Antimicrobial Chemotherapy. 78:569-585
This article reviews resistance to ceftazidime/avibactam as an aspect of its primary pharmacology, linked thematically with recent reviews of the basic in vitro and in vivo translational biology of the combination (J Antimicrob Chemother 2022; 77: 23
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3200b69eec0edfe1281bddc2534c8f0a
https://doi.org/10.1093/jac/dkac449
https://doi.org/10.1093/jac/dkac449
Autor:
David M. Shlaes, Patricia A. Bradford
Publikováno v:
Pathogens and Immunity, Vol 3, Iss 1, Pp 19-43 (2018)
To fully appreciate the importance of antibiotics to everyday life, we must step back to the edge of the pre-antibiotic era when these lifesaving drugs were first introduced into clinical use.
Externí odkaz:
https://doaj.org/article/ce7120db18db47c8a838d818425bf591
Publikováno v:
Journal of Antimicrobial Chemotherapy. 77:2341-2352
This review describes the translational in vivo and non-clinical pharmacokinetics/pharmacodynamics (PK/PD) research that supported clinical trialling and subsequently licensing approval of ceftazidime/avibactam, a new β-lactam/β-lactamase inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1693b1e1c53208944a1d033065a50ce9
https://doi.org/10.1093/jac/dkac172
https://doi.org/10.1093/jac/dkac172
Autor:
Karen Bush, David C. Hooper, Robert A. Bonomo, Patricia A. Bradford, George Eliopoulos, Pentti Huovinen, Antone A. Medeiros, Barbara Murray, Alain Philippon, Louis Rice
Publikováno v:
Antimicrob Agents Chemother
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5c8077eb9333a828c49d1776d7d9e5c
https://pubmed.ncbi.nlm.nih.gov/35506697
https://pubmed.ncbi.nlm.nih.gov/35506697
Autor:
Patricia A. Bradford, Robert A. Bonomo, Karen Bush, Alessandra Carattoli, Michael Feldgarden, Daniel H. Haft, Yoshikazu Ishii, George A. Jacoby, William Klimke, Timothy Palzkill, Laurent Poirel, Gian Maria Rossolini, Pranita D. Tamma, Cesar A. Arias
Publikováno v:
Antimicrobial Agents and Chemotherapy. 66
Assigning names to β-lactamase variants has been inconsistent and has led to confusion in the published literature. The common availability of whole genome sequencing has resulted in an exponential growth in the number of new β-lactamase genes. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60bee5056c483dde5560da810abd512c
https://doi.org/10.1128/aac.00333-22
https://doi.org/10.1128/aac.00333-22
Publikováno v:
ACS Infectious Diseases. 6:1332-1345
The Centers for Disease Control and the World Health Organization have issued a list of priority pathogens for which there are dwindling therapeutic options, including antibiotic-resistant Neisseri...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b899521bfb9fa374d8e09827df18734
https://doi.org/10.1021/acsinfecdis.0c00021
https://doi.org/10.1021/acsinfecdis.0c00021
Autor:
Ge Zhang, Ying Zhu, Qiwen Yang, Harald Reinhart, Patricia A. Bradford, Peiyao Jia, Jun Deng, Yingchun Xu, Meredith Hackel, Jingjia Zhang
Publikováno v:
Journal of Antimicrobial Chemotherapy. 75:1833-1839
BackgroundDurlobactam is a broad-spectrum inhibitor of class A, C and D β-lactamases. Sulbactam is a generic β-lactam most commonly used as a β-lactamase inhibitor in combination with ampicillin; however, it has a unique property in that it has se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8356d0010861269149f0593bd830e9e2
https://doi.org/10.1093/jac/dkaa119
https://doi.org/10.1093/jac/dkaa119
Publikováno v:
JAC-Antimicrobial Resistance
Extended-spectrum β-lactamase (ESBL)-producing Gram-negative pathogens are a major cause of resistance to expanded-spectrum β-lactam antibiotics. Since their discovery in the early 1980s, they have spread worldwide and an are now endemic in Enterob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae33e2f8c143fe7a5ea4c446f54947a0
https://doi.org/10.1093/jacamr/dlab092
https://doi.org/10.1093/jacamr/dlab092
Autor:
Karen Bush, Patricia A. Bradford
Publikováno v:
Nature Reviews Microbiology. 17:295-306
Resistance to β-lactam antibiotics in Gram-negative bacteria is commonly associated with production of β-lactamases, including extended-spectrum β-lactamases (ESBLs) and carbapenemases belonging to different molecular classes: those with a catalyt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d3143958a8f001b386406efcadbc146
https://doi.org/10.1038/s41579-019-0159-8
https://doi.org/10.1038/s41579-019-0159-8